期刊
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE
卷 4, 期 2, 页码 624-646出版社
AMER CHEMICAL SOC
DOI: 10.1021/acsptsci.0c00223
关键词
one-carbon metabolism; folate metabolism; SHMT2; MTHFD2; cancer; inhibitors
资金
- University of Michigan Pharmacological Sciences Training Program (PSTP) [T32-GM007767]
- NIH [R01 CA188252]
- University of Michigan Forbes Institute for Cancer Discovery
Metabolic reprogramming is a hallmark of cancer, with enzymes like SHMT2 and MTHFD2 in the folate cycle arm of the one-carbon metabolism pathway playing crucial clinical roles. This review discusses the function, regulation, and clinical relevance of SHMT2 and MTHFD2, as well as evaluating their prognostic significance across various cancers. Additionally, it provides an overview of inhibitors targeting the folate pathway, the methionine cycle, and other related enzymes for potential cancer therapy.
Metabolic reprogramming is a key hallmark of cancer and shifts cellular metabolism to meet the demands of biomass production necessary for abnormal cell reproduction. One-carbon metabolism (1CM) contributes to many biosynthetic pathways that fuel growth and is comprised of a complex network of enzymes. Methotrexate and 5-fluorouracil were pioneering drugs in this field and are still widely used today as anticancer agents as well as for other diseases such as arthritis. Besides dihydrofolate reductase and thymidylate synthase, two other enzymes of the folate cycle arm of 1CM have not been targeted clinically: serine hydroxymethyltransferase (SHMT) and methylenetetrahydrofolate dehydrogenase (MTHFD). An increasing body of literature suggests that the mitochondrial isoforms of these enzymes (SHMT2 and MTHFD2) are clinically relevant in the context of cancer. In this review, we focused on the 1CM pathway as a target for cancer therapy and, in particular, SHMT2 and MTHFD2. The function, regulation, and clinical relevance of SHMT2 and MTHFD2 are all discussed. We expand on previous clinical studies and evaluate the prognostic significance of these critical enzymes by performing a pan-cancer analysis of patient data from the The Cancer Genome Atlas and a transcriptional coexpression network enrichment analysis. We also provide an overview of preclinical and clinical inhibitors targeting the folate pathway, the methionine cycle, and folate-dependent purine biosynthesis enzymes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据